S2′-subsite variations between human and mouse enzymes (plasmin, factor XIa, kallikrein) elucidate inhibition differences by tissue factor pathway inhibitor -2 domain1-wild-type, Leu17Arg-mutant and aprotinin-Reference-Cited by-同舟云学术

S2′-subsite variations between human and mouse enzymes (plasmin, factor XIa, kallikrein) elucidate inhibition differences by tissue factor pathway inhibitor -2 domain1-wild-type, Leu17Arg-mutant and aprotinin

Published:2016-11-19 Issue:12 Volume:14 Page:2509-2523
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Vadivel K.¹,Kumar Y.¹,Ogueli G. I.¹,Ponnuraj S. M.¹,Wongkongkathep P.²,Loo J. A.²³,Bajaj M. S.⁴,Bajaj S. P.¹³

Affiliation:

1. Department of Orthopaedic Surgery; University of California; Los Angeles CA USA

2. Department of Chemistry and Biochemistry; University of California; Los Angeles CA USA

3. Molecular Biology Institute; University of California; Los Angeles CA USA

4. Division of Pulmonology and Critical Care; Department of Medicine; University of California; Los Angeles CA USA

Funder

National Heart, Lung, and Blood Institute

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.13538/fullpdf

Reference75 articles.

1. Plasmin-mediated fibrinolysis by variant recombinant tissue plasminogen activators;Urano;Proc Natl Acad Sci USA,1989

2. The cell biology of the plasminogen system;Plow;FASEB J,1995

3. Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma;Kashuk;Ann Surg,2010

4. The incidence and magnitude of fibrinolytic activation in trauma patients;Raza;J Thromb Haemost,2013

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision targeting of the plasminogen activator inhibitor‐1 mechanism increases efficacy of fibrinolytic therapy in empyema;Physiological Reports;2021-05

2. Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1;Journal of Clinical Medicine;2020-11-17

3. Precision Targeting of the Plasminogen Activator Inhibitor-1 Mechanism Increases Efficacy of Fibrinolytic Therapy in Empyema;2020-10-05

4. Plasma contact factors as therapeutic targets;Blood Reviews;2018-11